Paragonix Celebrates 100 th Kidney Transplant Case with FDA-Cleared KidneyVault™ System
WALTHAM, Mass.--(BUSINESS WIRE)-- Paragonix Technologies, a leader in organ transplant technologies and services, today announced the successful completion of its hundredth case using the FDA-cleared KidneyVault™ Portable Renal Perfusion System. This milestone was achieved with the support of Tennessee Donor Services (TDS), an Organ Procurement Organization (OPO) that serves more than 6 million people across Tennessee and Virginia.
In recent years, the transplantation industry has removed geographic barriers to ensure organs may reach those in greatest need, meaning organs now travel farther and remain outside the body longer. For kidney transport, the gold standard of preservation is hypothermic machine perfusion - a clinically accepted therapy that continuously pumps a specialized solution through the organ. The KidneyVault System is the first hypothermic machine perfusion device specifically designed to maximize mobility. The device offers a comprehensive, portable solution from end-to-end, allowing transplant teams to continuously perfuse the kidney and monitor key perfusion metrics in real-time through a mobile-friendly, data-driven dashboard.
The innovative system was first used shortly after achieving FDA clearance in late 2024 and has been rapidly adopted by likeminded organizations across the nation ever since. Now, over 12 OPOs stock the device, and 100 donor kidneys have been placed in a KidneyVault for transplant. This rapid adoption reflects a broader shift in the field — one that embraces new technology to meet the evolving demands of organ recovery and allocation.
'Tennessee Donor Services' mission is to save and improve lives through organ, eye, and tissue donation, and we're proud of our teams who embrace innovation to save as many lives as possible. It's exciting to partner with Paragonix to be an early adopter of the KidneyVault, a technology that will help more people get their lifesaving transplant, and work alongside their teams to make donation and transplant possible,' said Jill Grandas, CEO of Tennessee Donor Services.
Leading OPOs like Tennessee Donor Services are leveraging the KidneyVault System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In 2024, 27,761 kidney transplants were performed, highlighting the urgent need for innovative solutions to address the organ shortage.
"This hundredth KidneyVault case is a significant milestone for Paragonix and underscores our company's commitment to enhancing the future of organ transplantation," said Dr. Lisa Anderson, President of Paragonix Technologies. 'We are proud to offer advanced preservation technologies across all solid organ transplants, and our ability to provide a truly portable renal perfusion system aligns with our mission to provide ' Every Possible Advantage' to those waiting for lifesaving transplants.'
For more information about Paragonix Technologies, please visit paragonix.com.
About Tennessee Donor Services
An Extraordinary Commitment to Science, Health, and Hope
Tennessee Donor Services is a non-profit, organ procurement organization (OPO) dedicated to saving and improving lives by connecting organ and tissue donations to the patients who need them. TDS serves more than six million people in Tennessee and Virginia.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.
A Getinge company, Paragonix Technologies provides Advanced Organ Preservation ('AOP') devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Hyland expands its presence in India with a new office in Hyderabad
This marks a significant milestone in the company's global expansion strategy; enables access to technical expertise while strengthening the company's ability to serve customers globally NEW DELHI and HYDERABAD, India , June 10, 2025 /PRNewswire/ — Hyland, the pioneer of The Content Innovation Cloud™, is celebrating the official opening of its new office in Hyderabad , marking a significant milestone in the company's global expansion strategy, and mission to deliver breakthrough innovations to customers across the Asia Pacific region. The grand opening ceremony, held on 9 June 2025 , was graced by the presence of the US Consul General for Hyderabad , Ms. Jennifer Larson . Located in the heart of Hyderabad's prestigious Hitech City, the new facility represents Hyland's strategic investment in advancing The Content Innovation Cloud and accelerating customer success throughout Asia Pacific . This expansion positions the company to leverage the region's exceptional talent pool to drive next-generation innovations that transform how organizations manage, process, and unlock value from their content. ' Hyderabad's world-class technology ecosystem makes it the ideal location to advance The Content Innovation Cloud and deliver transformative solutions to our Asia Pacific customers,' said Tim McIntire , CTO at Hyland. 'This expansion directly supports our innovation agenda, enabling us to develop cutting-edge capabilities that help customers streamline operations, enhance productivity, and drive digital transformation. We're honored to have US Consul General Jennifer Larson join us for this momentous occasion, highlighting the power of US-India partnerships in advancing technological innovation.' The Hyderabad office will serve as a hub for innovation and customer success, housing critical functions focused on advancing The Content Innovation Cloud and delivering exceptional customer outcomes. This will drive product development, enhance customer enablement programs, and expand support capabilities to ensure Asia Pacific customers maximize value from Hyland's platform and solutions. The new facility is actively recruiting top talent to fuel Hyland's innovation engine across several key areas: Software Development professionals to architect and build next-generation capabilities within The Content Innovation Cloud to architect and build next-generation capabilities within The Content Innovation Cloud Professional Services specialists to accelerate customer implementations and drive successful digital transformation initiatives to accelerate customer implementations and drive successful digital transformation initiatives Customer Success coordinators to ensure customers achieve measurable business outcomes and maximize their return on investment to ensure customers achieve measurable business outcomes and maximize their return on investment Cloud and Technical Support experts to deliver world-class support and optimize customer experiences across cloud environments Hyland's new Hyderabad office joins its existing Kolkata location, reinforcing the company's global reach while creating significant employment opportunities, driving growth and customer success across the APAC region. To explore Hyland career opportunities in India , please visit the company's careers page at About Hyland Hyland empowers organizations with unified content, process and application intelligence solutions, unlocking profound insights that fuel innovation. Trusted by thousands of organizations worldwide, including many of the Fortune 100, Hyland's solutions fundamentally redefine how teams operate and engage with those they serve. For more information on Hyland, our products and solutions, please visit Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.
Business Upturn
an hour ago
- Business Upturn
Zen Technologies shares in focus after introducing Four-Barrel Rotary Machine Gun
Zen Technologies shares are in focus today after introducing its Four-Barrel Rotary Machine Gun, designed for counter-drone and high-intensity combat operations. The weapon features a rapid firing rate of up to 3,500 rounds per minute and an electronically operated firing mechanism, positioning it as a cutting-edge solution in modern warfare. Zen Technologies (@ZenTechnologies) Four-Barrel Rotary Machine Gun Featuring a firing rate of up to 3,500 rounds/min and dependable electronic operation, it stands as the premier weapon for counter-drone operations and intense combat scenarios. — Alpha Defense™🇮🇳 (@alpha_defense) June 10, 2025 The stock opened at ₹2,030.90 and touched an intraday high of ₹2,057.90, before slipping to a low of ₹2,015.00. It remains significantly below its 52-week high of ₹2,627.00 but well above the 52-week low of ₹945.35. As of 11:50 AM, the shares were trading 0.56% higher at Rs 2,025.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Wire
an hour ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
